CELLULAR LOGISTICS, INC.
Sun Prairie, WI · Founded 2016 · CIK 0001688621 · Biotech · Private
Cardiac fibroblast-derived extracellular matrix (CF-ECM), an injectable acellular biomaterial for post-myocardial infarction therapy
cellogistics.com →- Grants
- $1.3M
- 4 awards
- Sector median: 1
- Raised
- $1.0M
- 7 Form D · Apr 2025
- 18 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $185,000 | |
| Private capital raised | Form D · SEC | $4,958 | |
| Private capital raised | Form D · SEC | $617,664 | |
| Private capital raised | Form D · SEC | $75,000 | |
| Federal grant | Department of Health and Human Services · Phase I · iPSC-derived cardiac fibroblast extracellular matrix for cardiac cell therapy | $320,678 | |
| Federal grant | Department of Health and Human Services · Phase I · iPSC-derived cardiac fibroblast extracellular matrix for cardiac cell therapy | $320,678 | |
| Private capital raised | Form D · SEC | $37,500 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Evaluating Early and Late Functional, Immune and Angiogenic Responses to Injected Cardiac Fibroblast Derived Matrix in a Myocardial Infarction Model | $337,094 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Evaluating Early and Late Functional, Immune and Angiogenic Responses to Injected Cardiac Fibroblast Derived Matrix in a Myocardial Infarction Model | $337,094 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Private capital raised | Form D · SEC | $50,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2354 | Etheros Pharmaceuticals Corp. | — | $1.7M |
| 2355 | DeepCyte Inc. | — | $1.4M |
| 2356 | Unnatural Products Inc. | — | $23M |
| 2357 | CELLULAR LOGISTICS, INC. | — | $1.0M |
| 2358 | NEW EQUILIBRIUM BIOSCIENCES, INC. | — | $10M |
| 2359 | Metalytics, LLC | — | — |
| 2360 | OLIGOMERIX INC | — | $2.9M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Adam BockDirector · Executive Officer · Promoter
- Zach BowerExecutive Officer
- Peiman HemattiExecutive Officer · Promoter
- Amish RavalDirector · Executive Officer · Promoter
- Paul ResnickDirector
- Eric SchmuckExecutive Officer · Promoter
- Rakesh SoniDirector · Executive Officer
- Alex VodenlichDirector · Executive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.